Equities

Airsculpt Technologies Inc

AIRS:NMQ

Airsculpt Technologies Inc

Actions
Health CareHealth Care Providers
  • Price (USD)7.98
  • Today's Change-0.35 / -4.20%
  • Shares traded219.58k
  • 1 Year change+43.01%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Airsculpt Technologies Inc grew revenues 16.07% from 168.79m to 195.92m while net income improved from a loss of 14.68m to a smaller loss of 4.48m.
Gross margin65.39%
Net profit margin-1.77%
Operating margin4.35%
Return on assets-1.60%
Return on equity-4.11%
Return on investment-1.81%
More ▼

Cash flow in USDView more

In 2023, Airsculpt Technologies Inc increased its cash reserves by 6.72%, or 646.00k. The company earned 23.96m from its operations for a Cash Flow Margin of 12.23%. In addition the company used 9.92m on investing activities and also paid 13.39m in financing cash flows.
Cash flow per share0.1343
Price/Cash flow per share62.17
Book value per share1.48
Tangible book value per share-0.7067
More ▼

Balance sheet in USDView more

Airsculpt Technologies Inc has a Debt to Total Capital ratio of 45.41%, a lower figure than the previous year's 99.27%.
Current ratio0.8637
Quick ratio--
Total debt/total equity0.832
Total debt/total capital0.4541
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.